• P. N. Patsalos


Lamotrigine (Fig. 1) corresponds chemically to 3,5-diamino-6[2,3-dichlorophenyl]-1,2,4-triazine with an empirical formula of C9H7Cl2N5 and a molecular weight of 256.09.


Valproic Acid Pharmacokinetic Interaction Pharmacodynamic Interaction Eslicarbazepine Acetate Lamotrigine Monotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Weintraub D, Buchsbaum R, Resor SR, Hirsch LJ. Effect of ­antiepileptic drug comedication on lamotrigine clearance. Arch Neurol. 2005;62:1432–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Besag FM, Berry DJ, Pool F, Newbery JE, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia. 1998;39:183–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Armijo JA, Bravo J, Cuadrado A, Herranz JL. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther Drug Monit. 1999;21:182–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Almeida L, Nunes T, Sicard E, Rocha JF, Falcao A, Brunet JS, Lefebvre M, Soares-da-Silva P. Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. Acta Neurol Scand. 2010;121:257–64.PubMedCrossRefGoogle Scholar
  5. 5.
    Colucci R, Glue P, Holt B, Banfield C, Reidenberg P, Meehan JW, Pai S, Nomeir A, Lim J, Lin CC, Affrime MB. Effect of felbamate on the pharmacokinetics of lamotrigine. J Clin Pharmacol. 1996;36:634–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, Rosenow F, Doty P, Hebert D, Sullivan T. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia. 2009;50:443–53.PubMedCrossRefGoogle Scholar
  7. 7.
    Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide ­neurotoxicity associated with concomitant use of sodium-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav. 2011;20:20–3.PubMedCrossRefGoogle Scholar
  8. 8.
    Besag FM, Berry DJ, Pool F. Methsuximide lowers lamotrigine blood levels: a pharmacokinetic antiepileptic drug interaction. Epilepsia. 2000;41:624–7.PubMedCrossRefGoogle Scholar
  9. 9.
    May TW, Rambeck B, Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit. 1996;18:523–31.PubMedCrossRefGoogle Scholar
  10. 10.
    Rivas N, Buelga DS, Elger CE, Santos-Borbujo J, Otero MJ, Dominguez-Gil A, Garcia MJ. Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. Ther Drug Monit. 2008;30:483–9.PubMedGoogle Scholar
  11. 11.
    Zatreeh M, Tennison M, D’Cruz O, Beach RL. Anticonvulsant-induced chorea: a role for pharmacodynamic drug interaction? Seizure. 2001;10:596–9.CrossRefGoogle Scholar
  12. 12.
    Bockbrader HN, Burger P, Knapp L. Pregabalin effect on steady-state pharmacokinetics of carbamazepine, lamotrigine, phenobarbital, phenytoin, topiramate, valproate, and tiagabine. Epilepsia. 2011;52:405–9.PubMedGoogle Scholar
  13. 13.
    Hermann R, Knebel NG, Niebch G, Richards L, Borlak J, Locher M. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol. 2003;58:795–802.PubMedGoogle Scholar
  14. 14.
    Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49:1123–41.PubMedCrossRefGoogle Scholar
  15. 15.
    Summary of product characteristic, Sulthiame/Ospolot. 2009.Google Scholar
  16. 16.
    Berry DJ, Besag FMC, Pool F, Natarajan J, Doose D. Lack of effect of topiramate on lamotrigine serum concentrations. Epilepsia. 2002;43:818–23.PubMedCrossRefGoogle Scholar
  17. 17.
    Stephen LJ, Sills GJ, Brodie MJ. Lamotrigine and topiramate may be a useful combination. Lancet. 1998;351:958–9.PubMedGoogle Scholar
  18. 18.
    Kanner AM. When thinking of lamotrigine and valproic acid, think “pharmacokinetically”. Epilepsy Curr. 2004;4:206–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res. 1997;26:423–32.PubMedCrossRefGoogle Scholar
  20. 20.
    Reutens DC, Duncan JS, Patsalos PN. Disabling tremor after lamotrigine with sodium valproate. Lancet. 1993;342:185–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia. 1999;40:1141–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Mueller TH, Beeber AR. Delirium from valproic acid with lamotrigine. Am J Psychiatry. 2004;161:1128–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Stolarek I, Blacklaw J, Forrest G, Brodie MJ. Vigabatrin and lamotrigine in refractory epilepsy. J Neurol Neurosurg Psychiatry. 1994;57:921–4.PubMedCrossRefGoogle Scholar
  24. 24.
    Levy RH, Ragueneau-Majlessi I, Brodie MJ, Smith DF, Shah J, Pan WJ. Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. Ther Drug Monit. 2005;27:193–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations